Cognitive impairment and treatment strategy for atrial fibrillation in older adults: The SAGE-AF study

Deepti S Athreya; Jane S Saczynski; Jerry H Gurwitz; Kevin M Monahan; Benita A Bamgbade; Tenes J Paul; Felix Sogade; Darleen M Lessard; David D McManus; Robert H Helm

doi:10.1111/jgs.18949

Cognitive impairment and treatment strategy for atrial fibrillation in older adults: The SAGE-AF study

J Am Geriatr Soc. 2024 May 14. doi: 10.1111/jgs.18949. Online ahead of print.

Authors

Affiliations

¹ College of Science, Northeastern University, Boston, Massachusetts, USA.
² Department of Pharmacy and Health System Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts, USA.
³ Meyers Primary Care Institute and Division of Geriatric Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
⁴ Evans Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
⁵ Division of Cardiology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
⁶ Department of Medicine, Mercer University School of Medicine, Mercer, Georgia, USA.
⁷ Division of Epidemiology of Chronic Diseases, Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

PMID: 38742376
DOI: 10.1111/jgs.18949

Abstract

Background: Cognitive impairment is strongly associated with atrial fibrillation (AF). Rate and rhythm control are the two treatment strategies for AF and the effect of treatment strategy on risk of cognitive decline and frailty is not well established. We sought to determine how treatment strategy affects geriatric-centered outcomes.

Methods: The Systematic Assessment of Geriatric Elements-AF (SAGE-AF) was a prospective, observational, cohort study. Older adults with AF were prospectively enrolled between 2016 and 2018 and followed longitudinally for 2 years. In a non-randomized fashion, participants were grouped by rate or rhythm control treatment strategy based on clinical treatment at enrollment. Baseline characteristics were compared. Longitudinal binary mixed models were used to compare treatment strategy with respect to change in cognitive function and frailty status. Cognitive function and frailty status were assessed with the Montreal Cognitive Assessment Battery and Fried frailty phenotype tools.

Results: 972 participants (mean age = 75, SD = 6.8; 49% female, 87% non-Hispanic white) completed baseline examination and 2-year follow-up. 408 (42%) were treated with rate control and 564 (58%) with rhythm control. The patient characteristics of the two groups were different at baseline. Participants in the rate control group were older, more likely to have persistent AF, prior stroke, be treated with warfarin and have baseline cognitive impairment. After adjusting for baseline differences, participants treated with rate control were 1.5 times more likely to be cognitively impaired over 2 years (adjusted OR: 1.47, 95% CI:1.12, 1.98) and had a greater decline in cognitive function (adjusted estimate: -0.59 (0.23), p < 0.01) in comparison to rhythm control. Frailty did not vary between the treatment strategies.

Conclusions: Among those who had 2-year follow-up in non-randomized observational cohort, the decision to rate control AF in older adults was associated with increased odds of decline in cognitive function but not frailty.

Keywords: atrial fibrillation; cognitive impairment; frailty; older adults; rate versus rhythm control.

Abstract

Grants and funding